g2 Metastain™ - Test for Metastatic Cancer
BioStratum's collaborating laboratory at the Karolinska Institute, directed by BioStratum cofounder Dr. Tryggvason, was the first to discover that metastatic tumors produce the basal lamina protein laminin g2 at the tumor's invasive front. It appears that tumor cells utilize this protein in a basic mechanism of migration to invade surrounding tissue. This finding has been published in leading scientific journals and confirmed in a number of laboratories throughout the world.
Subsequent studies comparing the laminin g2
staining patterns of tumor biopsies and patient outcome (retrospective
studies) show a strong correlation between the level of laminin g2
detected and the presence of invasive, metastatic cancer. This pattern
has thus far been demonstrated for colon, cervical, breast, vaginal, and
larynx cancers, and other types of cancers are currently under investigation.
Our research indicates that in the case of cervical cancer, g2-Metastain™
can detect the presence